Condition (MeSH)
Splenomegaly
ClinicalTrials.gov lists 41 trials for Splenomegaly or a narrower condition beneath it. CENTOGENE GmbH Rostock has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
41 of the 41 trials are tagged with Splenomegaly itself; the rest are tagged with a narrower condition beneath it.
When did Splenomegaly trials start? (21)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 2 |
| 2021 | 2 |
| 2020 | 3 |
| 2019 | 2 |
| 2018 | 3 |
| 2017 | 4 |
| 2016 | 2 |
Showing 10 of 21 earlier years.
No forecast is made for this condition: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Splenomegaly trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 1/2 | 1 |
| Phase 2 | 7 |
| Phase 3 | 3 |
| Not applicable | 9 |
| Observational | 15 |
| Expanded access | 1 |
How many Splenomegaly trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 5 |
| Active, not recruiting | 2 |
| Completed | 17 |
| Terminated | 5 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Splenomegaly trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| CENTOGENE GmbH Rostock | 3 |
| CTI BioPharma | 2 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| Sanofi | 2 |
| AbbVie | 1 |
Which drugs are being tested for Splenomegaly? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Pyrimethamine | 2 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Ruxolitinib IR | 4 |
| A: pacritinib | 3 |
| Best Available Therapy | 2 |
| Navitoclax Dose Level 2 | 1 |
| Allogeneic Stem Cell Transplantation | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Splenomegaly trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Diarrhea | 55 | 1 |
| Fatigue | 44 | 2 |
| Pneumonia | 37 | 3 |
| Cough | 32 | 2 |
| Anemia | 24 | 3 |
Showing 5 of 10 adverse events.
Which publications cover Splenomegaly? (84)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| SplenoMegaly study (SMS): exploring the etiologies for "unexplained" splenomegalies in the real world. | Orphanet journal of rare diseases | 2025 | Yes |
| Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib. | JCO precision oncology | 2024 | Yes |
| Low prevalence of JAK2 V617F mutation in patients with thrombosis and normal blood counts: a retrospective impact study. | Journal of thrombosis and thrombolysis | 2020 | Yes |
| Clinical relevance of endpoints in clinical trials for acid sphingomyelinase deficiency enzyme replacement therapy. | Molecular genetics and metabolism | 2020 | Yes |
| Noncirrhotic Portal Hypertension: Current and Emerging Perspectives. | Clinics in liver disease | 2019 | Yes |
Showing 5 of 84 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.